key: cord-0774565-3b0za43x
authors: Matsumura, Yasufumi; Shimizu, Tsunehiro; Noguchi, Taro; Nakano, Satoshi; Yamamoto, Masaki; Nagao, Miki
title: Comparison of 12 Molecular Detection Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
date: 2020-11-28
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2020.11.007
sha: 28d4d9638eabd1eebdc520c63b573c0cc6f6e197
doc_id: 774565
cord_uid: 3b0za43x

Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the mainstay for accurate diagnosis of the infection, but the diagnostic performances of available assays have not been defined. We compared 12 molecular diagnostic assays, including 8 commercial kits using 155 respiratory samples (65 nasopharyngeal swabs, 45 oropharyngeal swabs, and 45 sputum) collected at 2 Japanese hospitals. Sixty-eight samples were positive for more than one assay and one genetic locus and were defined as true positive samples. All the assays showed a specificity of 100% (95% confidence interval, 95.8 to 100). The N2 assay kit of the US Centers for Disease Control and Prevention (CDC) and the N2 assay of the Japanese National Institute of Infectious Disease (NIID) were the most sensitive assays with 100% sensitivity (95% confidence interval, 94.7 to 100), followed by the CDC N1 kit, E assay by Corman, and NIID N2 assay multiplex with internal control reactions. These assays are reliable as first-line molecular assays in laboratories when combined with appropriate internal control reactions.

Accurate detection tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are important to combat the coronavirus disease 2019 (COVID-19) pandemic. 1 Various molecular diagnostic assays have been developed and used worldwide, [1] [2] [3] [4] but the differences in their diagnostic performances remain poorly understood. In this study, we aimed to compare the performance of 12 molecular assays.

A total of 923 upper or lower respiratory tract samples (nasopharyngeal swabs and oropharyngeal swabs in viral transport media or sputum) were collected from 446 patients who were suspected to have COVID-19 between January and May 2020 at Kyoto University Hospital and Kyoto City Hospital. In this study, we included all SARS-CoV-2-positive samples (n=68) from 39 patients with COVID-19 and 87 negative samples that were randomly selected from the remaining 855 samples. These negative samples were obtained from 69 patients, including 2 patients with COVID-19, of which samples were collected for follow-up testing. The N2 assay developed by the National Institute of Infectious Disease (NIID) in Japan 4 was employed as the routine assay and was used for the above sample selection process.

Sputum samples were liquified using semialkaline protease (Sputazyme;

Kyokuto Pharmaceutical Industrial, Tokyo, Japan) before further processing. The 

We determined the limit of detection (LOD) of each assay using a minimum J o u r n a l P r e -p r o o f of six replicates of two-fold or ten-fold serial dilutions of the heat-inactivated SARS-CoV-2 strain (ATCC VR-1986HK) starting from 1,000 genome copies/mL. If an assay could not detect 1,000 genome copies/mL, higher concentrations were assayed. We calculated the 95% limit of detection (LOD) using probit analysis.

At the time manuscript preparation, no gold standard existed. In this study, to ensure the presence of SARS-CoV-2 RNA and to avoid false-positives, a sample was defined as positive when positive test results were obtained for more than one genetic locus and assay and the others were defined as negative. The agreement of the assays was assessed by the Cohen's kappa concordance coefficient. The sensitivity and specificity were compared using the McNemar test.

The sensitivity of different specimen types was compared using the Fisher's exact test. The Ct values were compared using the Kruskal-Wallis test or a Mann-Whitney U test. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using SAS Studio 3.8 (SAS Institute Inc., Cary, NC).

This study was performed in line with the principles of the Declaration of Helsinki. The Ethics Committee of Kyoto University Graduate School and the Faculty of Medicine approved this study (R2379) and waived the need for obtaining informed consent from each patient.

Analytical sensitivity analysis showed that the LODs of the CDC N1, CDC N2, NIID N2 (with/without EAV), Corman E, and BGI assays were as low as <500 genome copies/mL sample (range, 240-391, corresponding to 2.8-4.6 copies/reaction; Table 2 ). The Thermo Combo and Roche E assays followed with J o u r n a l P r e -p r o o f LODs of <1000 genome copies/mL sample. The LODs of the Roche RdRP and N assays were higher than those of the abovementioned assays, ranging from 2,441 to 31,151 genome copies/mL sample. Table S1 .

All the assays exhibited a specificity of 100%, while sensitivity varied ( Table 3 ). The CDC N1, CDC N2, NIID N2 (with/without EAV), and Corman E assays were the most sensitive assays with ≥95.6% sensitivity. These 5 assays displayed high overall agreement compared with the reference standard (kappa values of ≥0.96) and between any two of them (kappa values of ≥0.95). The CDC N2 and NIID N2 assays exhibited 100% sensitivity; thus, their results were equal to the defined reference standard. The sensitivities of the remaining 7 assays (Corman N, Roche E, Roche RdRP, Roche N, Thermo Combo, BGI and LAMP assays; ≤88.2%) were significantly lower than those of the most sensitive assays.

The CDC protocol requires both N1 and N2 assays, and a sample will be considered positive if both produced positive results. In this study, one true positive nasopharygeal sample was positive only for the N2 assay even after retesting. The sample was considered inconclusive and the performance of the CDC protocol was considered the same as the CDC N1 assay. The NIID protocol includes both NIID N2 and Corman N assays, and a sample will be considered positive if either assay produces a positive result. In this study, 69. Table 4 shows the diagnostic performances for each specimen type.

Nasopharyngeal swabs had a higher sensitivity than those of the other samples in all assays. These differences in the sensitivities were statistically significant in the 

The current diagnosis of COVID-19 mainly relies on RT-PCR tests. 5 We performed manufacturer-independent evaluation of the molecular assays, including commercial kits that utilize otherwise-extracted RNA templates. We found that the specificity was perfect for all the assays and that the CDC N1, CDC N2, NIID N2, and Corman E assays were the most sensitive and highly concordant. 6 Genetic variations that may compromise sensitivity of the CDC N1, N2, and Corman E assays have been rarely observed as of week 21 of 2020. 7

False negatives by the other assays occurred among low-copy number samples (presenting high Ct values by the CDC N2 or NIID N2 assay; Supplemental Table   S1 ), suggesting a lack of sensitivity of these assays.

The Roche assays were based on Corman's assays 1 but had lower sensitivity for their E and N assays. This is likely due to lower Ct cutoffs for the Roche assays, rather than differences in reagents and reaction conditions (Table   1 and Supplemental Table S1 ). Previous studies reported that the N assay was less sensitive than the E assay 8 and the RdRP assay was less sensitive than the Roche E assay. 3 The low sensitivity of the Roche RdRP and N assays were concordant with their high LODs ( Table 2 ). The BGI assay exhibited a lower sensitivity than those of the other assays, which displayed similarly low LODs. This may be due to the inclusion of human gene internal controls in the same reaction, which could prevent amplification of viral genes, especially in human genome-enriched samples. The LAMP assay can be used in a resource-poor setting and has the fastest assay time due to its isothermal reaction. However, the J o u r n a l P r e -p r o o f Eiken LAMP kit used in this study had a low sensitivity and no control reaction. Viral loads vary depending on sampling methods and specimen types. One study reported higher viral loads in nasopharyngeal swabs than in oropharyngeal samples 9 and another study employing digital PCR reported viral loads were the To avoid false negatives due to technical errors such as extraction problems or PCR inhibition, it is recommended to include internal control reactions. The CDC assays were designed to be combined with a separate internal control reaction (Table 1) . Different from multiplex assays that incorporate internal controls such as Roche, Thermo Combo, or BGI kits, this approach needs extra reagents, time, and space in a reaction plate but can be combined with other in-house assays (NIID N2 or Corman E) without any modification. For the multiplex approach, we selected the NIID N2 assay to be multiplexed with the Roche EAV kit, resulting in the similar performance as the original NIID N2 assay. When compared with the Corman E assay, the R-Biopharm AG performed the best, followed by BGI, KH Medical, and Seegene. These reports are in agreement with our findings.

The study limitations included a relatively small sample size of each specimen type and lack of paired samples for all specimen types, clinical information, measurements by multiple investigators, and genomic variation analysis. Strengths included evaluation of multiple molecular assays using the same clinical samples. In addition, we validated the NIID N2 assay with EAV control reaction and determined the performance of the Thermo Combo kit and Eiken LAMP kit for the first time.

In conclusion, we found that the CDC EUA kit (N1/N2/RNaseP), NIID N2 with/without EAV, and Corman E assays were the most sensitive assays. They are feasible as references and clinical diagnostic tests until commercial kits with internal control reactions or fully automated systems that have high diagnostic performances are available without supply shortages in clinical laboratories.

Continuous efforts to improve COVID-19 diagnostics are important to control this pandemic. J o u r n a l P r e -p r o o f 

Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens